logo-loader
viewAmryt Pharma PLC

Amryt Pharma 'doing very well with strong cash and recurring revenues'

Amryt Pharma PLC's (LON:AMYT) Dr Joe Wiley tells Proactive London's Andrew Scott the business is well capitalised and resilient.

Pro forma revenues of the newly enlarged group were up 13.1% at US$154.1mln in the year just gone as it reported that a strong end to 2019 carried on into 2020.

Quick facts: Amryt Pharma PLC

Price: 100 GBX

AIM:AMYT
Market: AIM
Market Cap: £154.5 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Amryt Pharma well positioned to become 'global leader in...

Amryt Pharma PLC's (LON:AMYT) Rory Nealon talks Proactive London's Andrew Scott through their trading update for the nine months to the end of September 2019. It's a period in which Amryt completed the acquisition of Aegerion Pharmaceuticals Inc and saw the firm go from a single-product,...

on 5/11/19

2 min read